Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

COUCH Medcomms

- PMLiVE

Study reveals gut conditions could be early sign of Parkinson’s disease

Constipation, dysphagia and IBS could be potential biomarkers of the condition

- PMLiVE

New dementia risk score ‘calculator’ shown to strongly identify disease risk

Targeting key risk factors could potentially avert around 40% of dementia cases

- PMLiVE

The impact of storytelling in effective communication

Taking a human approach for bolder brand and portfolio narratives

- PMLiVE

Sandoz’s Tyruko approved by FDA as first biosimilar for relapsing multiple sclerosis

The disease-modifying therapy is approved to treat all indications covered by Tysabri

- PMLiVE

Pfizer’s RSV vaccine granted EC approval to protect infants and older adults

The decision allows Abrysvo to be given to those who are 24 to 36 weeks into their pregnancy

- PMLiVE

Vironix and Oxford University partner to advance chronic kidney disease monitoring

The partners will aim to develop learning models that predict the progression of CKD

- PMLiVE

Don’t lose sight of behavioural insight

If we are being asked to demonstrate ROI, we first need to agree on the value of the outcome

Top 10 Most Important Advisor Questions: Unmet Needs

As part of our top 10 most important advisor questions that every brand team should keep in mind when designing virtual advisory board touchpoints, here's the first one to keep...

Impetus Digital

- PMLiVE

Pfizer and Astellas’ Xtandi granted FDA priority review for new prostate cancer indication

The treatment is already approved in the US for three disease states of prostate cancer

- PMLiVE

Eli Lilly shares positive late-stage results for Retevmo in thyroid cancer

Medullary thyroid cancer only accounts for up to 2% of thyroid cancers in the US

- PMLiVE

US government awards $1.4bn for development of COVID-19 vaccines and therapeutics

The funding includes a contract with Regeneron for a next-generation antibody therapy

- PMLiVE

Study suggests self-reported information could help predict MS progression

Predicting MS progression could improve treatment and care outcomes for patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links